Roth Capital Remains Positive On Regeneron Pharmaceuticals Following 3Q14 Results
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $422, following the company’s results, posting diluted GAAP EPS of $0.70 vs. Roth’s estimate of $0.99.
Pantginis noted, “We are impressed by Eylea continued revenue growth, particularly ex-US, and expect a gradual and steady uptake in the newer approved macular edema indications. We look forward to 4Q14 results to see how Eylea prescriptions for DME sales are progressing following the drug’s recent approvals. Management indicated that uptake in Eylea prescriptions for DME (RVO including CRVO and BRVO) is expected to be slower than in wet AMD due to the dynamics of the disease and the physicians inclinations and knowledge of Eylea’s benefits in DME as shown in the Phase III studies.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -6.6% and a 42.9% success rate. Pantginis has a 32.9% average return when recommending REGN, and is ranked #3308 out of 3362 analysts.